Century Therapeutics Valuation Multiples

Century Therapeutics Overview

About Century Therapeutics

Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.

Founded

2018

HQ

Employees

150

Website

centurytx.com

Sectors

BiopharmaceuticalsBioTechDeepTech

Financials (LTM)

Revenue: $86M

Net Income: ($29M)

EV

$135M

Valuation Multiples

Multiples.vc

Start free trial

Century Therapeutics Financials

Century Therapeutics reported last 12-month revenue of $86M.

In the same LTM period, Century Therapeutics generated $86M in gross profit and had net loss of ($29M).

Century Therapeutics P&L

In the most recent fiscal year, Century Therapeutics reported revenue of $109M and EBITDA of $3M.

Century Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Century Therapeutics Stock Performance

Century Therapeutics has current market cap of $223M, and enterprise value of $135M.

Century Therapeutics' stock price is $2.55.

Century Therapeutics Valuation Multiples

Century Therapeutics trades at 1.6x EV/Revenue multiple, and 52.1x EV/EBITDA.

Century Therapeutics Financial Valuation Multiples

As of March 21, 2026, Century Therapeutics has market cap of $223M and EV of $135M.

Equity research analysts estimate Century Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Century Therapeutics has a P/E ratio of (7.6x).

Century Therapeutics Margins & Growth Rates

Century Therapeutics' revenue in the last 12 month declined by (100%).

Century Therapeutics' revenue per employee in the last FY averaged $0.6M.

Century Therapeutics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Century Therapeutics M&A Activity

Century Therapeutics acquired XXX companies to date.

Last acquisition by Century Therapeutics was on XXXXXXXX, XXXXX. Century Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Century Therapeutics Investment Activity

Century Therapeutics invested in XXX companies to date.

Century Therapeutics made its latest investment on XXXXXXXX, XXXXX. Century Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).